文献速递食管胃疾病与幽门螺杆菌消化道肿瘤与早癌

幽门螺杆菌除胃癌外的疾病负担:量化大规模根除治疗被忽视的潜在获益

The Disease Burden of Helicobacter pylori Beyond Gastric Cancer: Quantifying the Forgotten Potential Benefits of Mass Eradication.
PubMed 文献 · Gastroenterology · 2025-11-14

该研究通过系统文献检索计算幽门螺杆菌(Hp)归因于消化性溃疡病(PUD)、消化不良和胃淋巴瘤的人群归因分数(PAF),并估算全球及不同Hp流行国家可预防病例数。

要点

  • Hp归因于PUD、消化不良和胃淋巴瘤的PAF分别为57%、7%和33%。

核心结论

  • 将PUD和消化不良纳入Hp筛查治疗的成本效果和政策分析可更全面评估项目获益。
  • 仅关注胃癌会显著低估Hp根除的潜在健康收益。

研究设计与样本

  • 系统文献检索获取Hp导致PUD、消化不良和胃淋巴瘤的相对风险,计算人群归因分数(PAF)。
  • 基于根除治疗的风险降低估算全球及不同Hp流行国家的可预防病例数。

主要发现

  • PUD、消化不良和胃淋巴瘤归因于Hp的PAF(95%CI)分别为57%(44%-68%)、7%(2%-13%)和33%(12%-53%)。
  • 国家间PAF差异大,美国最低(PUD 35%、消化不良3%、胃淋巴瘤17%),韩国最高(PUD 63%、消化不良9%、胃淋巴瘤39%)。

关键数值与推荐

  • PUD归因Hp的PAF为57%(95%CI 44%-68%)。
  • 消化不良归因Hp的PAF为7%(95%CI 2%-13%)。
  • 胃淋巴瘤归因Hp的PAF为33%(95%CI 12%-53%)。

临床怎么用

  • 在Hp筛查治疗政策评估中应纳入PUD和消化不良结局以更全面量化获益。
  • 即使Hp低流行国家,根除治疗对PUD和消化不良仍有可观预防作用。

局限性

  • 实际获益取决于Hp是否在生命早期触发不可逆疾病通路。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Although Helicobacter pylori screen-and-treat has demonstrated effectiveness in preventing gastric cancer (GC), the impact on other diseases, such as peptic ulcer disease (PUD), dyspepsia, and gastric lymphomas, is often overlooked in guidelines and policy-analyses. This study quantifies the disease burden attributable to H pylori beyond GC. METHODS: A systematic literature search identified studies reporting the relative risk of developing PUD, dyspepsia, or gastric lymphomas due to H pylori to calculate the population attributable fraction (PAF) for each condition. The PAF represents the proportion of disease burden caused by H pylori. Preventable case numbers were calculated based on the risk reduction from eradication, both globally and specific for countries with varying H pylori prevalence. RESULTS: The proportions of PUD, dyspepsia, and gastric lymphoma attributable to H pylori (95% confidence interval) were 57% (44%-68%), 7% (2%-13%), and 33% (12%-53%), respectively, corresponding to 3.5 (2.7-4.2) million, 30 (7.1-52.2) million, and 12,000 (4200-19,100) cases potentially preventable through eradication, globally. Country-specific estimates varied with lowest PAFs (PUD, dyspepsia, gastric lymphomas) observed in the United States (35% [24%-47%], 3% [2%-13%], and 17% [5%-31%]) and highest in South Korea (63% [50%-73%], 9% [2%-15%], and 39% [14%-58%]). However, even in the United States, preventable case numbers remained substantial for PUD (134,000 [93,000-177,000]) and dyspepsia (860,000 [196,000-1.5 million]). CONCLUSIONS: Omitting PUD and dyspepsia as outcomes in studies on H pylori screen-and-treat may substantially underestimate benefits. Incorporating these diseases alongside GC into cost-effectiveness and policy analyses, therefore, may improve the evaluation of H pylori screen-and-treat programs. The actual benefit depends on the extent to which H pylori triggers an irreversible pathway to disease early in life.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Mülder DT, O'Mahony JF, Kapteijn N, et al. The Disease Burden of Helicobacter pylori Beyond Gastric Cancer: Quantifying the Forgotten Potential Benefits of Mass Eradication. Gastroenterology. 2025. PMID: 41236450. doi:10.1053/j.gastro.2025.08.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。